Last updated on May 2020

Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia


Brief description of study

This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed/refractory AML, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory AML

Clinical Study Identifier: NCT03616470

Find a site near you

Start Over

Cleveland Clinic

Cleveland, OH United States
  Connect »

Flinders Medical Centre

Bedford Park, Australia
  Connect »

Stanford Cancer Institute

Palo Alto, CA United States
  Connect »